Updated:
FendX Technologies
FendX Technologies develops nanotechnology-based films to reduce pathogen transmission on high-touch surfaces.
FendX Technologies
FendX Technologies focuses on commercializing surface protection nanotechnology that aims to reduce the spread of bacteria and other pathogens. The company's core work is based on licensed research, producing films and coatings designed to make surfaces less hospitable to microbial adhesion. As a publicly-traded life sciences venture, FendX's deployment activity is centered on research and development, regulatory validation, and early-stage commercialization of its protective film products. The company targets a technology-driven approach to infection control for high-traffic environments. It does not operate as an investment firm or manage third-party capital, but rather raises equity to fund its own product pipeline. Financial scale and team size are not widely disclosed, as is common with micro-cap public companies. The firm's primary activities involve advancing its proprietary coating technology through laboratory testing and towards market readiness, with public filings providing the main source of operational updates. What structurally distinguishes FendX is its status as a publicly-traded vehicle for a single, focused biotech application. The firm represents a direct public-market bet on a narrow material-science innovation aim to solve surface contamination challenges in healthcare and public spaces.
General information
Firm type
Unclassified
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
—
Corporate office
—
Sector focus
Frequently asked questions
What problem is FendX Technologies trying to solve?
FendX is developing protective films and coatings intended to reduce the adherence and transmission of pathogens on frequently-touched surfaces. The company's technology aims to lower infection risks without using traditional chemical disinfectants. The target environments include healthcare settings and other public spaces where surface contamination is a concern.
Is FendX an operating company or an investment firm?
FendX is an operating company focused on research, development, and commercialization of its surface protection technology. It is not a family office, asset manager, or fund. The company raises capital through public equity markets to fund its own product pipeline rather than investing in external ventures.
What is the core technology behind FendX's products?
FendX's technology is based on licensed nanotechnology research that creates surfaces engineered to repel bacteria and prevent biofilm formation. The approach focuses on physical surface modification rather than leaching antimicrobial chemicals. This aims to provide a durable, passive layer of protection on high-touch substrates.
Where is FendX Technologies headquartered?
FendX is based in Canada. Its public company status places it within the Canadian micro-cap life sciences sector. Additional operational or laboratory locations are not widely detailed in readily available public record.
What stage of development is FendX currently in?
FendX is an early-stage life sciences venture focused on pre-revenue research and development. The company is working towards regulatory approvals and commercialization partnerships for its protective film products. Details on specific clinical trial stages or market launch timelines would require review of its latest regulatory filings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: